Glucocorticoids are essential steroid hormones secreted from the adrenal gland in response to stress. Since their discovery in the 1940s, glucocorticoids have been widely prescribed to treat inflammatory disorders and hematological cancers. In the traditional view, glucocorticoids are regarded as anti-inflammatory molecules; however, emerging evidence suggests that glucocorticoid actions are more complex than previously anticipated. The anti-inflammatory activity of glucocorticoids is attributed to the repression of pro-inflammatory genes through signal transduction by their steroid receptor, the glucocorticoid receptor (GR). The mechanisms modulating the pro-inflammatory effects of glucocorticoids are not well understood. In this review, we discuss recent findings that provide insights into the mechanism by which GR signaling can play a dual role in the regulation of the immune response. We hypothesize that these apparently opposite processes are working together to prepare the immune system to respond to a stressor (pro-inflammatory effects) and subsequently restore homeostasis (anti-inflammatory effects). Finally, we propose that determining the mechanisms which underlie the tissue-specific effects of glucocorticoids will provide an excellent tool to develop more efficient and selective glucocorticoid therapies.

Keywords:
Glucocorticoids, Stress hormones, Glucocorticoid receptor, Inflammation, Immunity, Pro-inflammatory and anti-inflammatory
1.
Sapolsky RM, Romero LM, Munck AU: How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev 2000;21:55-89.
2.
Oakley RH, Cidlowski JA: The biology of the glucocorticoid receptor: new signaling mechanisms in health and disease. J Allergy Clin Immunol 2013;132:1033-1044.
3.
Kadmiel M, Cidlowski JA: Glucocorticoid receptor signaling in health and disease. Trends Pharmacol Sci 2013;34:518-530.
4.
Zhou J, Cidlowski JA: The human glucocorticoid receptor: one gene, multiple proteins and diverse responses. Steroids 2005;70:407-417.
5.
Vandevyver S, Dejager L, Tuckermann J, Libert C: New insights into the anti-inflammatory mechanisms of glucocorticoids: an emerging role for glucocorticoid-receptor-mediated transactivation. Endocrinology 2013;154:993-1007.
6.
Clark AR, Belvisi MG: Maps and legends: the quest for dissociated ligands of the glucocorticoid receptor. Pharmacol Ther 2012;134:54-67.
7.
Rhen T, Cidlowski JA: Antiinflammatory action of glucocorticoids - new mechanisms for old drugs. N Engl J Med 2005;353:1711-1723.
8.
Nussinovitch U, de Carvalho JF, Pereira RM, Shoenfeld Y: Glucocorticoids and the cardiovascular system: state of the art. Curr Pharm Des 2010;16:3574-3585.
9.
Miner JN, Hong MH, Negro-Vilar A: New and improved glucocorticoid receptor ligands. Expert Opin Investig Drugs 2005;14:1527-1545.
10.
Vanderbilt JN, Miesfeld R, Maler BA, Yamamoto KR: Intracellular receptor concentration limits glucocorticoid-dependent enhancer activity. Mol Endocrinol 1987;1:68-74.
11.
Danielsen M, Stallcup MR: Down-regulation of glucocorticoid receptors in mouse lymphoma cell variants. Mol Cell Biol 1984;4:449-453.
12.
Silva CM, Lu H, Weber MJ, Thorner MO: Differential tyrosine phosphorylation of JAK1, JAK2, and STAT1 by growth hormone and interferon-gamma in IM-9 cells. J Biol Chem 1994;269:27532-27539.
13.
Barnes PJ, Adcock IM: Glucocorticoid resistance in inflammatory diseases. Lancet 2009;373:1905-1917.
14.
Busillo JM, Cidlowski JA: The five Rs of glucocorticoid action during inflammation: ready, reinforce, repress, resolve, and restore. Trends Endocrinol Metab 2013;24:109-119.
15.
Whitfield GK, Jurutka PW, Haussler CA, Haussler MR: Steroid hormone receptors: evolution, ligands, and molecular basis of biologic function. J Cell Biochem 1999;suppl 32-33:110-122.
16.
Hollenberg SM, Weinberger C, Ong ES, Cerelli G, Oro A, Lebo R, Thompson EB, Rosenfeld MG, Evans RM: Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature 1985;318:635-641.
17.
Nicolaides NC, Galata Z, Kino T, Chrousos GP, Charmandari E: The human glucocorticoid receptor: molecular basis of biologic function. Steroids 2010;75:1-12.
18.
Beck IM, De Bosscher K, Haegeman G: Glucocorticoid receptor mutants: man-made tools for functional research. Trends Endocrinol Metab 2011;22:295-310.
19.
Beato M: Gene regulation by steroid hormones. Cell 1989;56:335-344.
20.
Freedman LP: Anatomy of the steroid receptor zinc finger region. Endocr Rev 1992;13:129-145.
21.
Uhlenhaut NH, Barish GD, Yu RT, Downes M, Karunasiri M, Liddle C, Schwalie P, Hubner N, Evans RM: Insights into negative regulation by the glucocorticoid receptor from genome-wide profiling of inflammatory cistromes. Mol Cell 2013;49:158-171.
22.
De Bosscher K, Vanden Berghe W, Haegeman G: Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors. J Neuroimmunol 2000;109:16-22.
23.
De Bosscher K, Vanden Berghe W, Vermeulen L, Plaisance S, Boone E, Haegeman G: Glucocorticoids repress NF-κB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell. Proc Natl Acad Sci USA 2000;97:3919-3924.
24.
So AY, Chaivorapol C, Bolton EC, Li H, Yamamoto KR: Determinants of cell and gene-specific transcriptional regulation by the glucocorticoid receptor. PLoS Genet 2007;3:e94.
25.
Surjit M, Ganti KP, Mukherji A, Ye T, Hua G, Metzger D, Li M, Chambon P: Widespread negative response elements mediate direct repression by agonist-liganded glucocorticoid receptor. Cell 2011;145:224-241.
26.
Ayroldi E, Cannarile L, Migliorati G, Nocentini G, Delfino DV, Riccardi C: Mechanisms of the anti-inflammatory effects of glucocorticoids: genomic and nongenomic interference with MAPK signaling pathways. Faseb J 2012;26:4805-4820.
27.
Lee SR, Kim HK, Youm JB, Dizon LA, Song IS, Jeong SH, Seo DY, Ko KS, Rhee BD, Kim N, et al: Non-genomic effect of glucocorticoids on cardiovascular system. Pflügers Arch 2012;464:549-559.
28.
Yudt MR, Cidlowski JA: Molecular identification and characterization of A and B forms of the glucocorticoid receptor. Mol Endocrinol 2001;15:1093-1103.
29.
Gross KL, Cidlowski JA: Tissue-specific glucocorticoid action: a family affair. Trends Endocrinol Metab 2008;19:331-339.
30.
Oakley RH, Sar M, Cidlowski JA: The human glucocorticoid receptor β isoform. Expression, biochemical properties, and putative function. J Biol Chem 1996;271:9550-9559.
31.
Oakley RH, Cidlowski JA: Cellular processing of the glucocorticoid receptor gene and protein: new mechanisms for generating tissue-specific actions of glucocorticoids. J Biol Chem 2011;286:3177-3184.
32.
Bamberger CM, Bamberger AM, de Castro M, Chrousos GP: Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans. J Clin Invest 1995;95:2435-2441.
33.
Kino T, Su YA, Chrousos GP: Human glucocorticoid receptor isoform beta: recent understanding of its potential implications in physiology and pathophysiology. Cell Mol Life Sci 2009;66:3435-3448.
34.
Lewis-Tuffin LJ, Cidlowski JA: The physiology of human glucocorticoid receptor beta (hGRβ) and glucocorticoid resistance. Ann NY Acad Sci 2006;1069:1-9.
35.
Kino T, Manoli I, Kelkar S, Wang Y, Su YA, Chrousos GP: Glucocorticoid receptor (GR) β has intrinsic, GRα-independent transcriptional activity. Biochem Biophys Res Commun 2009;381:671-675.
36.
Avenant C, Ronacher K, Stubsrud E, Louw A, Hapgood JP: Role of ligand-dependent GR phosphorylation and half-life in determination of ligand-specific transcriptional activity. Mol Cell Endocrinol 2010;327:72-88.
37.
Wang Z, Frederick J, Garabedian MJ: Deciphering the phosphorylation ‘code' of the glucocorticoid receptor in vivo. J Biol Chem 2002;277:26573-26580.
38.
Webster JC, Jewell CM, Bodwell JE, Munck A, Sar M, Cidlowski JA: Mouse glucocorticoid receptor phosphorylation status influences multiple functions of the receptor protein. J Biol Chem 1997;272:9287-9293.
39.
Miller AL, Webb MS, Copik AJ, Wang Y, Johnson BH, Kumar R, Thompson EB: p38 mitogen-activated protein kinase (MAPK) is a key mediator in glucocorticoid-induced apoptosis of lymphoid cells: correlation between p38 MAPK activation and site-specific phosphorylation of the human glucocorticoid receptor at serine 211. Mol Endocrinol 2005;19:1569-1583.
40.
Chen W, Dang T, Blind RD, Wang Z, Cavasotto CN, Hittelman AB, Rogatsky I, Logan SK, Garabedian MJ: Glucocorticoid receptor phosphorylation differentially affects target gene expression. Mol Endocrinol 2008;22:1754-1766.
41.
Galliher-Beckley AJ, Williams JG, Collins JB, Cidlowski JA: Glycogen synthase kinase 3β-mediated serine phosphorylation of the human glucocorticoid receptor redirects gene expression profiles. Mol Cell Biol 2008;28:73097322.
42.
Galliher-Beckley AJ, Williams JG, Cidlowski JA: Ligand-independent phosphorylation of the glucocorticoid receptor integrates cellular stress pathways with nuclear receptor signaling. Mol Cell Biol 2011;31:4663-4675.
43.
Wallace AD, Cidlowski JA: Proteasome-mediated glucocorticoid receptor degradation restricts transcriptional signaling by glucocorticoids. J Biol Chem 2001;276:42714-42721.
44.
Druker J, Liberman AC, Antunica-Noguerol M, Gerez J, Paez-Pereda M, Rein T, Iniguez-Lluhi JA, Holsboer F, Arzt E: RSUME enhances glucocorticoid receptor SUMOylation and transcriptional activity. Mol Cell Biol 2013;33:2116-2127.
45.
Ito K, Yamamura S, Essilfie-Quaye S, Cosio B, Ito M, Barnes PJ, Adcock IM: Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-κB suppression. J Exp Med 2006;203:7-13.
46.
Charmandari E, Chrousos GP, Lambrou GI, Pavlaki A, Koide H, Ng SS, Kino T: Peripheral CLOCK regulates target-tissue glucocorticoid receptor transcriptional activity in a circadian fashion in man. PLoS One 2011;6:e25612.
47.
Sorrells SF, Sapolsky RM: An inflammatory review of glucocorticoid actions in the CNS. Brain Behav Immun 2007;21:259-272.
48.
Dhabhar FS: Stress-induced augmentation of immune function - the role of stress hormones, leukocyte trafficking, and cytokines. Brain Behav Immun 2002;16:785-798.
49.
Dhabhar FS, McEwen BS: Enhancing versus suppressive effects of stress hormones on skin immune function. Proc Natl Acad Sci USA 1999;96:1059-1064.
50.
Deinzer R, Granrath N, Stuhl H, Twork L, Idel H, Waschul B, Herforth A: Acute stress effects on local Il-1β responses to pathogens in a human in vivo model. Brain Behav Immun 2004;18:458-467.
51.
O'Connor KA, Johnson JD, Hansen MK, Wieseler Frank JL, Maksimova E, Watkins LR, Maier SF: Peripheral and central proinflammatory cytokine response to a severe acute stressor. Brain Res 2003;991:123-132.
52.
Bowers SL, Bilbo SD, Dhabhar FS, Nelson RJ: Stressor-specific alterations in corticosterone and immune responses in mice. Brain Behav Immun 2008;22:105-113.
53.
Akira S, Uematsu S, Takeuchi O: Pathogen recognition and innate immunity. Cell 2006;124:783-801.
54.
Pancer Z, Cooper MD: The evolution of adaptive immunity. Annu Rev Immunol 2006;24:497-518.
55.
Bhattacharyya S, Brown DE, Brewer JA, Vogt SK, Muglia LJ: Macrophage glucocorticoid receptors regulate Toll-like receptor 4-mediated inflammatory responses by selective inhibition of p38 MAP kinase. Blood 2007;109:4313-4319.
56.
Tuckermann JP, Kleiman A, Moriggl R, Spanbroek R, Neumann A, Illing A, Clausen BE, Stride B, Forster I, Habenicht AJ, et al: Macrophages and neutrophils are the targets for immune suppression by glucocorticoids in contact allergy. J Clin Invest 2007;117:1381-1390.
57.
Barnes PJ: How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br J Pharmacol 2006;148:245-254.
58.
Hess J, Angel P, Schorpp-Kistner M: AP-1 subunits: quarrel and harmony among siblings. J Cell Sci 2004;117(pt 25):5965-5973.
59.
Johnson GL, Lapadat R: Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002;298:1911-1912.
60.
Kumar A, Takada Y, Boriek AM, Aggarwal BB: Nuclear factor-κB: its role in health and disease. J Mol Med (Berl) 2004;82:434-448.
61.
Liden J, Delaunay F, Rafter I, Gustafsson J, Okret S: A new function for the C-terminal zinc finger of the glucocorticoid receptor: repression of RelA transactivation. J Biol Chem 1997;272:21467-21472.
62.
Reily MM, Pantoja C, Hu X, Chinenov Y, Rogatsky I: The GRIP1:IRF3 interaction as a target for glucocorticoid receptor-mediated immunosuppression. Embo J 2006;25:108-117.
63.
McKay LI, Cidlowski JA: CBP (CREB binding protein) integrates NF-κB (nuclear factor-κB) and glucocorticoid receptor physical interactions and antagonism. Mol Endocrinol 2000;14:1222-1234.
64.
Nissen RM, Yamamoto KR: The glucocorticoid receptor inhibits NFκB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev 2000;14:2314-2329.
65.
Murphy SH, Suzuki K, Downes M, Welch GL, De Jesus P, Miraglia LJ, Orth AP, Chanda SK, Evans RM, Verma IM: Tumor suppressor protein (p)53, is a regulator of NF-κB repression by the glucocorticoid receptor. Proc Natl AcadSci USA 2011;108:17117-17122.
66.
Smoak K, Cidlowski JA: Glucocorticoids regulate tristetraprolin synthesis and posttranscriptionally regulate tumor necrosis factor alpha inflammatory signaling. Mol Cell Biol 2006;26:9126-9135.
67.
Carrick DM, Lai WS, Blackshear PJ: The tandem CCCH zinc finger protein tristetraprolin and its relevance to cytokine mRNA turnover and arthritis. Arthritis Res Ther 2004;6:248-264.
68.
Dhabhar FS: A hassle a day may keep the doctor away: stress and the augmentation of immune function. Integr Comp Biol 2002;42:556-564.
69.
Chinenov Y, Rogatsky I: Glucocorticoids and the innate immune system: crosstalk with the toll-like receptor signaling network. Mol Cell Endocrinol 2007;275:30-42.
70.
Galon J, Franchimont D, Hiroi N, Frey G, Boettner A, Ehrhart-Bornstein M, O'Shea JJ, Chrousos GP, Bornstein SR: Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. Faseb J 2002;16:61-71.
71.
Homma T, Kato A, Hashimoto N, Batchelor J, Yoshikawa M, Imai S, Wakiguchi H, Saito H, Matsumoto K: Corticosteroid and cytokines synergistically enhance toll-like receptor 2 expression in respiratory epithelial cells. Am J Respir Cell Mol Biol 2004;31:463-469.
72.
Hermoso MA, Matsuguchi T, Smoak K, Cidlowski JA: Glucocorticoids and tumor necrosis factor alpha cooperatively regulate Toll-like receptor 2 gene expression. Mol Cell Biol 2004;24:4743-4756.
73.
Shuto T, Imasato A, Jono H, Sakai A, Xu H, Watanabe T, Rixter DD, Kai H, Andalibi A, Linthicum F, et al: Glucocorticoids synergistically enhance nontypeable Haemophilus influenzae-induced Toll-like receptor 2 expression via a negative cross-talk with p38 MAP kinase. J Biol Chem 2002;277:17263-17270.
74.
Bornstein SR, Zacharowski P, Schumann RR, Barthel A, Tran N, Papewalis C, Rettori V, McCann SM, Schulze-Osthoff K, Scherbaum WA, et al: Impaired adrenal stress response in Toll-like receptor 2-deficient mice. Proc Natl AcadSci USA 2004;101:16695-16700.
75.
Lannan EA, Galliher-Beckley AJ, Scoltock AB, Cidlowski JA: Proinflammatory actions of glucocorticoids: glucocorticoids and TNFα coregulate gene expression in vitro and in vivo. Endocrinology 2012;153:3701-3712.
76.
Langlais D, Couture C, Balsalobre A, Drouin J: Regulatory network analyses reveal genome-wide potentiation of LIF signaling by glucocorticoids and define an innate cell defense response. PLoS Genet 2008;4:e1000224.
77.
Busillo JM, Azzam KM, Cidlowski JA: Glucocorticoids sensitize the innate immune system through regulation of the NLRP3 inflammasome. J Biol Chem 2011;286:38703-38713.
78.
Ding Y, Gao ZG, Jacobson KA, Suffredini AF: Dexamethasone enhances ATP-induced inflammatory responses in endothelial cells. J Pharmacol Exp Ther 2010;335:693-702.
79.
Brewer JA, Khor B, Vogt SK, Muglia LM, Fujiwara H, Haegele KE, Sleckman BP, Muglia LJ: T-cell glucocorticoid receptor is required to suppress COX-2-mediated lethal immune activation. Nat Med 2003;9:1318-1322.
80.
Kim CJ, Woo YJ, Kim GH, Yoo HW: Familial glucocorticoid deficiency with a point mutation in the ACTH receptor: a case report. J Korean Med Sci 2009;24:979-981.
81.
Duma D, Collins JB, Chou JW, Cidlowski JA: Sexually dimorphic actions of glucocorticoids provide a link to inflammatory diseases with gender differences in prevalence. Sci Signal 2010;3:ra74.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.